In an effort to support the next generation of leading Alzheimer’s researchers, the Cure Alzheimer’s Fund has joined with the Alzheimer’s Association and the Lou Ruvo Brain Institute to create and fund a new “genius grant” for young Alzheimer’s researchers. The new prize called Tomorrowās Leaders in Alzheimerās Disease Research honors ...
February 19, 2007
AsĀ reportedĀ recently in theĀ New York Times (Business Day, March 20, 2015, āBiogen Reports Its Alzheimerās Drug Sharply Slows Cognitive Declineā) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I āhuman safetyā trial of a new drug designed to treat ā and possibly prevent ā Alzheimerās ...
March 23, 2015
The Alzheimerās Genome Projectā¢ (AGP) , funded by Cure Alzheimerās Fund (CAF), is making great scientific progress. This work is providing new understanding of AD pathology and revealing novel genetic information. The more we know about how the disease works, the better the chances are for identifying therapeutic intervention and ...
December 15, 2010
Dr. Cheryl Wellington is Professor and Vice Chair of Research, Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Center for Brain Health, University of British Columbia. Her translational research interests include Alzheimerās Disease, Traumatic Brain Injury and neurology blood biomarkers. Dr. Wellington holds multiple leadership and executive positions in the ...
April 18, 2016
Meg Smith, Chief Executive Officer Dear Friends, As summer comes to a close, I am delighted to share an update on our progress and achievements dedicated to advancing research in understanding Alzheimerās disease (AD). Your support and dedication are instrumental in driving our mission forward, and it is with great pride that ...
September 6, 2024
The study, led by Cure Alzheimerās Research Consortium member Sam Gandy, M.D., Ph.D., of the Icahn School of Medicine at Mount Sinai, examined how elements in air pollution such as nickel nanoparticles affect the levels of certain peptides in the brain that are found to be at heightened levels in ...
April 15, 2013
Largest Single Private Investment in Alzheimerās Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimerās Drug Development Understanding who is most susceptible to Alzheimerās disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private ...
October 18, 2012
Dear Friends, Why should you care about Alzheimerās research? Currently, for every dollar spent on Alzheimerās care, only a penny is spent working toward a cure. This is a bad equation for a disease that is estimated will cost well more than $100 billion in care (Medicare and Medicaid alone) in 2009. Ā Cure ...
January 4, 2010
Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Womenās Hospital, and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. Vijay Kuchroo is also an Institute member of the Broad Institute and a senior investigator ...
November 15, 2021
By John R. Cirrito, Ph.D., and David M. Holtzman, M.D.Microdialysis Core Facility, Department of Neurology, Hope Center for Neurological Diseases, Washington University, St. Louis, MO A major contributing factor in Alzheimerās disease is the elevation of a protein called amyloid-Ī², or AĪ². Since high levels of AĪ² play a role in ...
August 20, 2009
